Green tea catechins and cardiovascular disease risk factors: Should a health claim be made by the United States Food and Drug Administration?

被引:14
|
作者
Murray, Morgan [1 ]
Walchuk, Chelsey [1 ]
Suh, Miyoung [1 ]
Jones, Peter J. [1 ]
机构
[1] Univ Manitoba, Richardson Ctr Funct Foods & Nutraceut, Dept Human Nutr Sci, Winnipeg, MB R3T 6C5, Canada
关键词
DOUBLE-BLIND; INSULIN-RESISTANCE; CONSUMPTION; EXTRACT; SUPPLEMENTATION; GLUCOSE; OBESE; CHOLESTEROL; TOXICITY; CANCER;
D O I
10.1016/j.tifs.2014.10.004
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Green tea (Camellia sinensis) is an ancient beverage stemming from China, more recently gaining interest in Western societies due to its antioxidant capacity. Cardiovascular disease (CVD), a disease of the heart and blood vessels, is a result of increased lipid concentrations and blood pressure, responsible for numerous deaths worldwide. Green tea is highly enriched in catechins, which may be responsible for its proposed CVD prevention mechanism. The objective of this paper was to examine the scientific evidence pertaining to green tea and CVD risk and evaluate whether enough credible scientific evidence exists to support a health claim by the United States Food and Drug Administration (US FDA). Sixteen clinical studies have examined the effects of green tea on CVD risk factors however, following a critical evaluation of these studies, a health claim cannot be recommended due to the safety and metabolites of green tea, as well due to lack of high quality and properly designed studies.
引用
收藏
页码:188 / 197
页数:10
相关论文
共 50 条
  • [21] VASECTOMY AND RISK OF CARDIOVASCULAR-DISEASE IN THE UNITED-STATES PHYSICIANS HEALTH STUDY
    MANSON, JE
    BURING, JE
    HENNEKENS, CH
    CIRCULATION, 1990, 81 (02) : 729 - 729
  • [22] LETS PUT THE TRIALS TO A TEST: A 23 YEAR REVIEW OF UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) RECORDS OF CARDIOVASCULAR DISEASE CLINICAL TRIALS
    Olorunfemi, Odunayo
    Ogunbayo, Gbolahan
    Ojo, Amole
    Ojo, Rebecca
    Ola, Olatunde
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 2491 - 2491
  • [23] Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease
    Li, Roger
    Tabayoyong, William B.
    Guo, Charles C.
    Gonzalez, Graciela M. Nogueras
    Navai, Neema
    Grossman, H. Barton
    Dinney, Colin P.
    Kamat, Ashish M.
    EUROPEAN UROLOGY, 2019, 75 (01) : 8 - 10
  • [24] Current Trends in Reducing Cardiovascular Risk Factors in the United States: Focus on Worksite Health and Wellness
    Cahalin, Lawrence P.
    Myers, Jonathan
    Kaminsky, Leonard
    Briggs, Paige
    Forman, Daniel E.
    Patel, Mahesh J.
    Pinkstaff, Sherry O.
    Arena, Ross
    PROGRESS IN CARDIOVASCULAR DISEASES, 2014, 56 (05) : 476 - 483
  • [25] Five-Year Trends in Risk Factors for Cardiovascular Disease Among Adolescents in the United States
    Hasan, Ali
    Ramphul, Kamleshun
    Ahmed, Raheel
    Farhan, Muzammil
    Hassan, Azeem
    Dachepally, Rashmitha
    Almasri, Murad
    Ahmad, Hasan
    Carver, Caleb
    Jeelani, Mohammad Saddam
    CIRCULATION, 2023, 148
  • [26] Have income and education related disparities in cardiovascular disease risk factors improved in the United States?
    Kanjilal, S
    Cheng, YJ
    Gregg, EW
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 161 (11) : S50 - S50
  • [27] Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
    Zheng, Yi
    Guo, Xiaojing
    Chen, Chenxin
    Chi, Lijie
    Guo, Zhijian
    Liang, Jizhou
    Wei, Lianhui
    Chen, Xiao
    Ye, Xiaofei
    He, Jia
    PHARMACEUTICALS, 2023, 16 (01)
  • [28] Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines
    Nacif, Marcelo S.
    Arai, Andrew E.
    Lima, Joao A. C.
    Bluemke, David A.
    JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2012, 14
  • [29] Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines
    Marcelo S Nacif
    Andrew E Arai
    Joao AC Lima
    David A Bluemke
    Journal of Cardiovascular Magnetic Resonance, 14
  • [30] Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors
    Sone, Toshimasa
    Kuriyama, Shinichi
    Nakaya, Naoki
    Hozawa, Atsushi
    Shimazu, Taichi
    Nomura, Kozue
    Rikimaru, Shouzo
    Tsuji, Ichiro
    FOOD & NUTRITION RESEARCH, 2011, 55